ClinicalTrials.gg
CompletedNCT02723591ASTOUNDUpdated Dec 18, 2024Results posted

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients

A Phase 4 interventional study of Tacrolimus and Tacrolimus immediate release in Kidney Transplantation, sponsored by Astellas Pharma Global Development, Inc.. Completed at 30 sites in United States. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
599
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Study summary

This study compared the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a designation of immune activation (IA) on peripheral blood molecular profiling in participants maintained on twice daily, immediate-release tacrolimus versus those maintained on Astagraf XL in the first year post-transplant.

Read the detailed description

This was an exploratory, two year (shortened to 1 year due to a stopping rule necessitated by the adaptive design), prospective, randomized, multi-center, open-label trial examining long-term kidney transplant outcomes through the use of an adaptive design and a two-part, composite surrogate endpoint. Specifically, it was designed to compare the effects of twice daily, immediate-release tacrolimus and once daily Astagraf XL on DSA formation and the development of a peripheral blood molecular profile indicating the presence of IA in de novo kidney transplant recipients during the first year following transplantation. For the purposes of this study, IA was defined as a positive molecular signature using a molecular assay in all participants.

Participants were screened prior to surgery and randomized 1:1 to receive immediate-release tacrolimus, administered twice daily, or Astagraf XL, as a component of a standard immunosuppression maintenance regimen also consisting of corticosteroids (if given per institutional protocol) and mycophenolate mofetil (MMF) (or Myfortic® equivalent). Investigators were encouraged to start participants on the randomized study treatment (immediate release tacrolimus or Astagraf XL) within 48 hours of transplantation (pre-transplant administration of study treatment was not allowed). However, if medically indicated per the treating physician's discretion, initiation of study treatment was delayed for up to seven days post-transplant.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • FK506
  • Kidney Transplantation
  • Tacrolimus
  • Astagraf XL
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recipient of a de novo kidney from a living or deceased donor. Note: Recipient of an en bloc deceased donor kidney transplant from a pediatric donor ≥5 years of age AND weighing greater than 20 kg is allowed.
  • If deceased donor, a Kidney Donor Profile Index (KDPI) ≤ 85 (Donation after Circulatory Death [DCD] and what was previously known as extended criteria donor [ECD] organ recipients are eligible for enrollment provided KDPI ≤85).
  • At least one antigen mismatch at major Major Histocompatibility Complex (MHC) (class I or class II).
  • Willingness to comply with study protocol.
  • Subject agrees not to participate in another drug study while on treatment.
  • Female subject must be either:

    a. Of non- i. (defined as at least 1 year without any menses) prior to screening, or ii. Documented surgically sterile or status post-hysterectomy b. Or, if of childbearing potential, i. Agree not to try to become pregnant during the study and for 90 days after the final study drug administration ii. And have a negative serum or urine pregnancy test within 7 days prior to transplant procedure iii. And, if heterosexually active, agree to consistently use two forms of highly effective (at least one of which must be a barrier method) which includes consistent and correct usage of established oral contraception, established intrauterine device or intrauterine system, or barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository or vasectomy in the male partner, starting at screening and throughout the study period and for 90 days after the final study drug administration.

  • Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at screening and continuing throughout the study period and for 90 days after the final study drug administration.
  • Male subject must not donate sperm starting at screening throughout the study period and for 90 days after the final study drug administration.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 90 days after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period, and for 90 days after the final study drug administration.
  • Will be receiving induction immunotherapy (either T-cell depleting agent, anti-CD52 monoclonal antibody, or Interleukin-2 (IL-2) co-stimulation blocker), with dose and frequency of the chosen induction agent determined by local standard of care. -only induction therapy does not satisfy this criterion.

Exclusion criteria

Exclusion Criteria:

  • Patient is known to have a positive test for latent Tuberculosis (TB) and has not previously received adequate anti-microbial therapy or would require TB prophylaxis after transplant.
  • Uncontrolled concomitant infection or any unstable medical condition that could interfere with study objectives.
  • Significant liver disease, defined as having, during the past 28 days, consistently elevated , GOT (AST) Serum Glutamic Oxaloacetic Transaminase (SGOT) and/or Alanine Aminotransferase, GPT (ALT) Serum Glutamic Pyruvic Transaminase (SPGT) levels greater than 3 times the upper value of the normal range of the site.
  • Patient currently taking or maintained on another form of extended-release tacrolimus following his/her transplant procedure.
  • Patient who will be maintained on a non-tacrolimus-based maintenance regimen following his/her transplant procedure.
  • Patient currently taking, having taken within 30 days, or who will be maintained on an Mammalian target of rapamycin (mTOR) inhibitor following his/her transplant procedure.
  • Use of an investigational study drug in the 30 days prior to the transplant procedure.
  • or to drugs or any of their components that constitute the immunosuppression regimen.
  • 6 Antigen (Ag) match or zero mismatch at major Major Histocompatibility Complex (MHC) (class I or class II).
  • Receipt of an Blood Group System (A, B, AB, and O) (ABO)-incompatible organ. Note: A2 donor to O recipient or A2 donor to B recipient is considered ABO-compatible and not excluded by this criterion.
  • Presence of current or historic pre-formed anti-Human Leukocyte Antigen (HLA) DSA against the current donor (evidence of pre-formed, non-donor HLA is not exclusionary) as defined by a subject meeting any of the following criteria*: a) positive virtual crossmatch, b) positive T- or B-cell crossmatch by National Institutes of Health (NIH) antiglobulin lymphocytotoxicity method** , c) .Positive T- or B-cell flow cytometry crossmatch defined by the Multiparameter flow cytometry (MFC) criteria used by the center's HLA lab for their local proficiency testing.,** d) An Mean Fluorescence Intensity (MFI) greater than or approaching 1000 using flow cytometry/Luminex-based, specific anti-HLA antibody testing.

    • * Patients are eligible to enroll with a negative virtual crossmatch if used in lieu of a physical crossmatch, if, use of such is required to obviate the accrual of excessive ischemia time. However, continued participation is predicated on the performance of the physical crossmatch within 48 hours of transplant. If the physical crossmatch is positive, the subject will be discontinued.
    • ** If b or c above are positive secondary to a suspected positive auto-crossmatch, that is not exclusionary as long as a and b above are not met.
  • Receipt of desensitization, antibody-removal, anti-B-cell, or anti-plasma cell therapy in the 90 days preceding the transplant procedure.
  • Planned initiation (prior to transplant) of desensitization, antibody-removal, anti-B-cell, or anti-plasma cell therapy within 7 days of the transplant procedure.
  • Donor or recipient with known infection (Hepatitis C Virus (HCV) antibody positive), (HIV) infection (HIV antibody positive), acute infection (Hepatitis B Surface Antigen (HBsAg) positive, anti-Hepatitis B Virus Core (HBc) positive, Immunoglobulin M (IgM) anti-HBc positive, anti-HBs negative) chronic hepatitis B infection (HBsAg positive, anti-HBc positive, IgM anti-HBc negative, anti-HBs negative), or equivocal hepatitis B status (HBsAg negative, anti-HBc positive, anti-HBs negative). Patients (donor or recipient) who have normal liver function tests (LFT) and who are either hepatitis C positive with a negative viral load or have natural or vaccine-acquired immunity from hepatitis B are not excluded by this criterion.
  • Primary focal segmental glomerulosclerosis.
  • Subject has a current or history of malignancy (within the past 5 years), except non- basal or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix that has been successfully treated.
  • Recipient of multi-organ or dual kidney transplants (inclusive of current transplant and any prior non-renal transplants). Note: Patients with prior kidney transplants are eligible.
  • Recipient of an en bloc, pediatric deceased donor kidney from a donor less than 5 years of age OR weighing less than 20 kg.
  • Prior graft loss secondary to Cytomegalovirus (CMV) or BK nephropathy.
  • Prior history of invasive organ disease in the presence of CMV or BKV or CMV viremia.
  • History of clinically significant BK viruria.
  • Any condition which makes the subject unsuitable for study participation.
  • Planned complete avoidance (Steroid initiation and subsequent taper / withdrawal will be allowed and will be under the purview of the treating physician).
  • Planned receipt of post-transplant prophylactic HCV treatment.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
599 participants (actual)

Study arms

  • Active comparator
    Tacrolimus, Extended Release (Astagraf XL®) Once Daily

    Participants received tacrolimus extended release (Astagraf XL) at a starting dose of 0.15 milligram per kilogram (mg/kg), once daily, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 nanogram per milliliter (ng/mL) at all times during the study.

    Drug: Tacrolimus

  • Active comparator
    Tacrolimus, Immediate Release Twice Daily (BID)

    Participants received tacrolimus immediate release as per the institutionally-derived protocol, BID, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 ng/mL at all times during the study.

    Drug: Tacrolimus immediate release

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Were Positive for de Novo DSA (dnDSA) or Immune Activation (IA) Occurrence

    DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching mean fluorescence intensity (MFI)=1000 at any time during the study. IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.

    Time frame: From date of transplant until 1 year

Secondary outcomes

  1. Percentage of Participants Who Were Positive, Negative or Indeterminate for dnDSA Occurrence

    DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study. Indeterminate was defined as MFI signal was \>1000 and DSA was suspected, but could not be confirmed due to inadequate donor typing. Participants whose samples for the test were not available were reported as unknown.

    Time frame: From date of transplant until 1 year

  2. Peak Mean Fluorescence Intensity (MFI) of DSA Positive Participants

    Peak MFI of DSA positive participants was reported.

    Time frame: From date of transplant until 1 year

  3. Percentage of DSA Positive Participants With Weak, Moderate and Strong Antibody Strentgh

    DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study.

    Time frame: From date of transplant until 1 year

  4. Percentage of DSA Positive Participants With DSA Persistence

    DSA was regarded as persistent under the following conditions: (i) DSA was detected and remained above the threshold for positivity (MFI = 1000) for two consecutive or nonconsecutive measurements, or (ii) the new appearance of a DSA at the threshold for positivity when preceded by a DSA of a different specificity that had subsequently become non-detectable.

    Time frame: From date of transplant until 1 year

  5. Percentage of Participants Who Were Positive or Negative for Complement Component 1, Q Subcomponent (C1q)-Binding DSA

    Percentage of participants who were positive or negative for C1q-binding DSA were reported.

    Time frame: From date of transplant until 1 year

  6. Percentage of Participants Who Were Positive or Negative for DSA Immunoglobulin G (IgG3) Isotype

    Percentage of participants who were positive or negative for IgG3 isotype were reported.

    Time frame: From date of transplant until 1 year

  7. Percentage of DSA Positive Participants With Human Leukocyte Antigen, Class II, DQ Locus (HLA-DQ)

    Percentage of DSA positive participants with HLA-DQ Class-II were reported.

    Time frame: From date of transplant until 1 year

  8. Percentage of Participants Who Were Positive for IA Occurrence From Day 1 to Day 365 Visit

    IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.

    Time frame: From day 1 to day 365 visit

  9. Percentage of Participants Who Were Positive for IA Occurrence From Day 30 to Day 365 Visit

    IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.

    Time frame: From day 30 to day 365 visit

  10. Percentage of Participants With IA Persistence

    IA was regarded as persistent under the following conditions: (i) IA was detected and remained above the threshold for positivity for two consecutive or non-consecutive measurements, or (ii) the new appearance of an IA at the threshold for positivity when preceded by an IA of a different specificity that had subsequently become non-detectable.

    Time frame: From date of transplant until 1 year

  11. Percentage of Participants With Presence of Transplant Glomerulopathy (TG) on Biopsy

    TG was defined as chronic glomerulopathy (cg) \>0 on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year post-transplant with +2 months visit window.

    Time frame: From date of transplant until month 14

  12. Percentage of Participants With Presence of Microcirculatory Inflammation (MI) on Biopsy

    MI was defined as glomerulitis (g) + peritubular capillaritis (ptc)\>=2 on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year post-transplant, with +2 months visit window.

    Time frame: From date of transplant until month 14

  13. Percentage of Participants With Presence of Interstitial Fibrosis and Tubular Atrophy (IFTA) and Inflammation on Biopsy

    IFTA and inflammation was defined as IFTA positive and inflammation positive (i \>0) on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year posttransplant, with +2 months visit window.

    Time frame: From date of transplant until month 14

  14. Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Threshold of <30 Millimetre Per Minute Per 1.73 Meter Square (mL/Min/1.73m^2)

    The eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.

    Time frame: At 1 year post transplant

  15. Percentage of Participants With eGFR Threshold of <40 mL/Min/1.73m^2

    The eGFR was calculated using the MDRD formula.

    Time frame: At 1 year post transplant

  16. Percentage of Participants With eGFR Threshold of <50 mL/Min/1.73m^2

    The eGFR was calculated using the MDRD formula.

    Time frame: At 1 year post transplant

  17. Percentage of Participants With a Five-point Decline in eGFR

    The eGFR was calculated using the MDRD formula.

    Time frame: From 30 days post transplant until 1 year

  18. eGFR at Day 30, Day 90, Day 180, Day 270 and Day 365

    The eGFR was calculated using the MDRD formula.

    Time frame: Day 30, day 90, day 180, day 270 and day 365

  19. Percentage of Participants With Graft Loss

    Graft loss was defined as re-transplantation, transplant nephrectomy, or a return to dialysis for at least a six week duration, or participants' death.

    Time frame: From date of transplant until 1 year

  20. Percentage of Participants Who Died

    Percentage of participants who died were reported.

    Time frame: From date of transplant until 1 year

  21. Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)

    Positivity was determined by local biopsy, central pathology, or reported adverse events.

    Time frame: From date of transplant until 1 year

  22. Percentage of Participants Who Were Lost to Follow-up

    Percentage of participants who were lost to follow-up were reported.

    Time frame: From date of transplant until 1 year

  23. Percentage of Participants With Either Graft Loss, Death, BPAR or Lost to Follow-up

    Percentage of participants with either graft loss, death, BPAR or lost to follow-up were reported.

    Time frame: From date of transplant until 1 year

  24. Percentage of Participants With Any Antibody-Mediated Rejection (ABMR)

    Percentage of participants with ABMR were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. A positive assessment is defined as antibody mediated changes that are diagnosed as either acute ABMR or chronic active ABMR.

    Time frame: From date of transplant until month 14

  25. Percentage of Participants With Normal Biopsy Findings

    Percentage of participants with normal biopsy findings were reported.

    Time frame: From date of transplant until month 14

  26. Percentage of Participants With C4d Deposition Without Active Rejection

    Percentage of participants with C4d deposition without active rejection were reported.

    Time frame: From date of transplant until month 14

  27. Percentage of Participants With Acute ABMR

    Percentage of participants with acute ABMR were reported.

    Time frame: From date of transplant until month 14

  28. Percentage of Participants With Grade I, II and III Acute ABMR

    Percentage of participants with grade I, II and III acute ABMR were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Acute ABMR was graded as Grade I: acute tubular necrosis-like -like minimal inflammation, Grade II: Capillary and or glomerular inflammation (ptc/g \>0) and/or thromboses, and Grade III: arterial - v3.

    Time frame: From date of transplant until month 14

  29. Percentage of Participants With Chronic ABMR

    Percentage of participants with chronic ABMR were reported.

    Time frame: From date of transplant until month 14

  30. Percentage of Participants With Borderline Changes

    Percentage of participants with borderline changes were reported.

    Time frame: From date of transplant until month 14

  31. Percentage of Participants With Acute T-cell Mediated Rejection (TCMR)

    Percentage of participants with acute TCMR were reported.

    Time frame: From date of transplant until month 14

  32. Percentage of Participants With Chronic TCMR

    Percentage of participants with chronic TCMR were reported.

    Time frame: From date of transplant until month 14

  33. Percentage of Participants With Grade I, II and III IFTA

    Percentage of participants with Grade I, II and III IFTA were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. IFTA was graded as Grade I: mild interstitial fibrosis and tubular atrophy (\<25% of cortical area), Grade II: moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area), and Grade III: severe interstitial fibrosis and tubular atrophy/ loss (\>50% of cortical area).

    Time frame: From date of transplant until month 14

  34. Percentage of Participants With Any Additional Findings

    Percentage of participants with any additional findings (other than Normal biopsy, borderline changes, acute and chronic ABMR, Grade I, II, and III ABMR, C4D deposition, acute and chronic TCMR, Grade I, II, and III TCMR, Grade I, II and III IFTA, acute tubular necrosis, interstitial nephritis, pyelonephritis, bk virus, calcineurin inhibitor toxicity, hemolytic uremic syndrome and recurrent disease) were reported.

    Time frame: From date of transplant until month 14

  35. Percentage of Participants With Glomerulitis (g) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No glomerulitis, Score 1= \<25% glomerulitis, Score 2= 25 to 75% glomerulitis and Score 3= \>75% glomerulitis.

    Time frame: From date of transplant until month 14

  36. Percentage of Participants With Tubulitis (t) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No mononuclear cells in tubules or single focus of tubulitis only, Score 1= Foci with 1 to 4 mononuclear cells/tubular cross section (or 10 tubular cells), Score 2= Foci with 5 to 10 mononuclear cells/tubular cross section (or 10 tubular cells) and Score 3= Foci with \>10 mononuclear cells/tubular cross section or the presence of ≥2 areas of tubular basement membrane destruction accompanied by i2/i3 inflammation and t2 elsewhere.

    Time frame: From date of transplant until month 14

  37. Percentage of Participants With Intimal Arteritis (v) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No arteritis, Score 1= Mild to moderate intimal arteritis in at least 1 arterial cross section, Score 2= Severe intimal arteritis with at least 25% luminal area lost in at least 1 arterial cross section and Score 3= Transmural arteritis and/or arterial fibrinoid change and medial smooth muscle necrosis with lymphocytic infiltrate in vessel.

    Time frame: From date of transplant until month 14

  38. Percentage of Participants With Mononuclear Cell Interstitial Inflammation (i) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No inflammation or in less than 10% of unscarred cortical parenchyma, Score 1= Inflammation in 10 to 25% of unscarred cortical parenchyma, Score 2= Inflammation in 26 to 50% of unscarred cortical parenchyma and Score 3= Inflammation in more than 50% of unscarred cortical parenchyma.

    Time frame: From date of transplant until month 14

  39. Percentage of Participants With Glomerular Basement Membrane Double Contours (cg) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No GBM double contours by light microscopy (LM) or electron microscopy (EM), Score 1= No GBM double contours by LM but GBM double contours (incomplete or circumferential) in at least 3 glomerular capillaries by EM or Double contours of the GBM in 1-25% of capillary loops in the most affected nonsclerotic glomerulus by LM , Score 2= Double contours affecting 26 to 50% of peripheral capillary loops in the most affected-glomerulus and Score 3= Double contours affecting more than 50% of peripheral capillary loops in the most affected-glomerulus.

    Time frame: From date of transplant until month 14

  40. Percentage of Participants With Tubular Atrophy (ct) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No tubular atrophy, Score 1= Tubular atrophy involving up to 25% of the area of cortical tubules, Score 2= Tubular atrophy involving 26 to 50% of the area of cortical tubules and Score 3= Tubular atrophy involving in \>50% of the area of cortical tubules.

    Time frame: From date of transplant until month 14

  41. Percentage of Participants With Interstitial Fibrosis (ci) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= Interstitial fibrosis in up to 5% of cortical area, Score 1= Interstitial fibrosis in 6 to 25%of cortical area (mild interstitial fibrosis), Score 2= Interstitial fibrosis in 26 to 50% of cortical area (moderate interstitial fibrosis) and Score 3= Interstitial fibrosis in \>50% of cortical area (severe interstitial fibrosis).

    Time frame: From date of transplant until month 14

  42. Percentage of Participants With Vascular Fibrous Intimal Thickening (cv) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No chronic vascular changes, Score 1= Vascular narrowing of up to 25% luminal area by fibrointimal thickening, Score 2= Vascular narrowing of 26 to 50% luminal area by fibrointimal thickening and Score 3= Vascular narrowing of more than 50% luminal area by fibrointimal thickening.

    Time frame: From date of transplant until month 14

  43. Percentage of Participants With Arteriolar Hyalinosis (ah) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No periodic acid-Schiff (PAS)-positive hyaline arteriolar thickening, Score 1= Mild to moderate PAS-positive hyaline thickening in at least 1 arteriole, Score 2= Moderate to severe PAS-positive hyaline thickening in more than 1 arteriole and Score 3= Severe PAS-positive hyaline thickening in many arterioles.

    Time frame: From date of transplant until month 14

  44. Percentage of Participants With Peritubular Capillaritis (Ptc) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= Maximum number of leukocytes \<3, Score 1= At least 1 leukocyte cell in ≥10% of cortical PTCs with 3-4 leukocytes in most severely involved PTC, Score 2= At least 1 leukocyte in ≥10% of cortical PTC with 5-10 leukocytes in most severely involved PTC and Score 3= At least 1 leukocyte in ≥10% of cortical PTC with \>10 leukocytes in most severely involved PTC.

    Time frame: From date of transplant until month 14

  45. Percentage of Participants With Mesangial Matrix Expansion (mm) Biopsy Score Assessed Using Banff Lesion Scores

    Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No more than mild mesangial matrix increase in any glomerulus, Score 1= At least moderate mesangial matrix increase in up to 25% of nonsclerotic glomeruli, Score 2= At least moderate mesangial matrix increase in 26% to 50% of nonsclerotic glomeruli and Score 3= At least moderate mesangial matrix increase in \>50% of nonsclerotic glomeruli.

    Time frame: From date of transplant until month 14

  46. Time to First Occurrence of DSA

    DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study.

    Time frame: From date of transplant until 1 year

  47. Time to First Occurrence of HLA-DQ DSA

    Time to first occurrence of HLA-DQ DSA was reported.

    Time frame: From date of transplant until 1 year

  48. Time to First Occurrence of C1q-binding DSA

    Time to first occurrence of C1q-binding DSA was reported.

    Time frame: From date of transplant until 1 year

  49. Time to First Occurrence of DSA IgG3 Isotype

    Time to first occurrence of DSA IgG3 isotype was reported.

    Time frame: From date of transplant until 1 year

  50. Time to First Occurrence of IA

    Time to first occurrence of IA was reported.

    Time frame: From date of transplant until 1 year

  51. Time to First Occurrence of TG on Biopsy

    Time to first occurrence of TG on biopsy was reported.

    Time frame: From date of transplant until 1 year

  52. Time to Occurrence of Death

    Time to occurrence of death was reported.

    Time frame: From date of transplant until 1 year

  53. Time to First Occurrence of Local BPAR

    Time to first occurrence of local BPAR was reported.

    Time frame: From date of transplant until 1 year

  54. Time to First Occurrence of Acute Forms of ABMR

    Time to first occurrence of acute forms of ABMR was reported.

    Time frame: From date of transplant until 1 year

  55. Time to First Occurrence of Chronic Forms of ABMR

    Time to first occurrence of chronic forms of ABMR was reported.

    Time frame: From date of transplant until 1 year

  56. Time to First Occurrence of Acute TCMR

    Time to first occurrence of acute TCMR was reported.

    Time frame: From date of transplant until 1 year

  57. Time to First Occurrence of Chronic TCMR

    Time to first occurrence of chronic TCMR was reported.

    Time frame: From date of transplant until 1 year

  58. Time to First Occurrence of Borderline Changes

    Time to first occurrence of borderline changes was reported.

    Time frame: From date of transplant until 1 year

  59. Time to First Occurrence of IFTA

    Time to first occurrence of IFTA was reported.

    Time frame: From date of transplant until 1 year

  60. Percentage of Participants With Treatment-emergent Adverse Event(TEAEs), Related TEAEs, Treatment-emergent Serious Adverse Event (TESAEs), Related TESAEs, TEAEs Leading to Discontinuation of Study Treatment and TEAEs Leading to Death

    A TEAE was defined as an Adverse Event (AE) observed on or after the day of starting the administration of the test drug/comparative drug.

    Time frame: From first dose of study drug up to 7 days after last dose of study drug (up to 2 years)

07

Results

Posted Jun 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release Twice Daily (BID)
Started300299
Completed204198
Not completed96101
Withdrew: Adverse event4840
Withdrew: Death22
Withdrew: Lack of efficacy43
Withdrew: Lost to follow-up17
Withdrew: Protocol violation2023
Withdrew: Withdrawal by subject48
Withdrew: Randomized but never received studydrug1212
Withdrew: Miscellaneous56

Outcome measures

PrimaryPercentage of Participants Who Were Positive for de Novo DSA (dnDSA) or Immune Activation (IA) Occurrence

DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching mean fluorescence intensity (MFI)=1000 at any time during the study. IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Positive for de Novo DSA (dnDSA) or Immune Activation (IA) Occurrence
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants Who Were Positive for de Novo DSA (dnDSA) or Immune Activation (IA) Occurrence35.634.4
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Regression, Logistic · p = 0.5777 · Odds ratio (or): 1.115 · 95% CI 0.760 to 1.636
SecondaryPercentage of Participants Who Were Positive, Negative or Indeterminate for dnDSA Occurrence

DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study. Indeterminate was defined as MFI signal was \>1000 and DSA was suspected, but could not be confirmed due to inadequate donor typing. Participants whose samples for the test were not available were reported as unknown.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Positive, Negative or Indeterminate for dnDSA Occurrence
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Positive5.54.3
Negative90.592.8
Indeterminate42.5
Unknown00.4
SecondaryPeak Mean Fluorescence Intensity (MFI) of DSA Positive Participants

Peak MFI of DSA positive participants was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Median · fluorescence intensity unit
Peak Mean Fluorescence Intensity (MFI) of DSA Positive Participants
fluorescence intensity unitTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Peak Mean Fluorescence Intensity (MFI) of DSA Positive Participants6119.21 (1320.0 to 29317.6)2727.99 (1066.0 to 19971.5)
SecondaryPercentage of DSA Positive Participants With Weak, Moderate and Strong Antibody Strentgh

DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of DSA Positive Participants With Weak, Moderate and Strong Antibody Strentgh
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Weak00
Moderate73.383.3
Strong26.716.7
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.6618
SecondaryPercentage of DSA Positive Participants With DSA Persistence

DSA was regarded as persistent under the following conditions: (i) DSA was detected and remained above the threshold for positivity (MFI = 1000) for two consecutive or nonconsecutive measurements, or (ii) the new appearance of a DSA at the threshold for positivity when preceded by a DSA of a different specificity that had subsequently become non-detectable.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of DSA Positive Participants With DSA Persistence
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of DSA Positive Participants With DSA Persistence73.350
SecondaryPercentage of Participants Who Were Positive or Negative for Complement Component 1, Q Subcomponent (C1q)-Binding DSA

Percentage of participants who were positive or negative for C1q-binding DSA were reported.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Positive or Negative for Complement Component 1, Q Subcomponent (C1q)-Binding DSA
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Positive1.80.4
Negative98.299.6
SecondaryPercentage of Participants Who Were Positive or Negative for DSA Immunoglobulin G (IgG3) Isotype

Percentage of participants who were positive or negative for IgG3 isotype were reported.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Positive or Negative for DSA Immunoglobulin G (IgG3) Isotype
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Positive0.71.1
Negative99.398.9
SecondaryPercentage of DSA Positive Participants With Human Leukocyte Antigen, Class II, DQ Locus (HLA-DQ)

Percentage of DSA positive participants with HLA-DQ Class-II were reported.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of DSA Positive Participants With Human Leukocyte Antigen, Class II, DQ Locus (HLA-DQ)
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of DSA Positive Participants With Human Leukocyte Antigen, Class II, DQ Locus (HLA-DQ)4025
SecondaryPercentage of Participants Who Were Positive for IA Occurrence From Day 1 to Day 365 Visit

IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.

Time frame:
From day 1 to day 365 visit
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Positive for IA Occurrence From Day 1 to Day 365 Visit
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants Who Were Positive for IA Occurrence From Day 1 to Day 365 Visit31.331.2
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Regression, Logistic · p = 0.8518 · Odds ratio (or): 1.038 · 95% CI 0.700 to 1.539
SecondaryPercentage of Participants Who Were Positive for IA Occurrence From Day 30 to Day 365 Visit

IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.

Time frame:
From day 30 to day 365 visit
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Positive for IA Occurrence From Day 30 to Day 365 Visit
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants Who Were Positive for IA Occurrence From Day 30 to Day 365 Visit21.821.9
SecondaryPercentage of Participants With IA Persistence

IA was regarded as persistent under the following conditions: (i) IA was detected and remained above the threshold for positivity for two consecutive or non-consecutive measurements, or (ii) the new appearance of an IA at the threshold for positivity when preceded by an IA of a different specificity that had subsequently become non-detectable.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants With IA Persistence
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With IA Persistence7.310
SecondaryPercentage of Participants With Presence of Transplant Glomerulopathy (TG) on Biopsy

TG was defined as chronic glomerulopathy (cg) \>0 on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year post-transplant with +2 months visit window.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Presence of Transplant Glomerulopathy (TG) on Biopsy
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Presence of Transplant Glomerulopathy (TG) on Biopsy6.56.6
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 1.0000
SecondaryPercentage of Participants With Presence of Microcirculatory Inflammation (MI) on Biopsy

MI was defined as glomerulitis (g) + peritubular capillaritis (ptc)\>=2 on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year post-transplant, with +2 months visit window.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Presence of Microcirculatory Inflammation (MI) on Biopsy
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Presence of Microcirculatory Inflammation (MI) on Biopsy8.95.9
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.4750
SecondaryPercentage of Participants With Presence of Interstitial Fibrosis and Tubular Atrophy (IFTA) and Inflammation on Biopsy

IFTA and inflammation was defined as IFTA positive and inflammation positive (i \>0) on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year posttransplant, with +2 months visit window.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Presence of Interstitial Fibrosis and Tubular Atrophy (IFTA) and Inflammation on Biopsy
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Presence of Interstitial Fibrosis and Tubular Atrophy (IFTA) and Inflammation on Biopsy2616.9
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.0939
SecondaryPercentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Threshold of <30 Millimetre Per Minute Per 1.73 Meter Square (mL/Min/1.73m^2)

The eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.

Time frame:
At 1 year post transplant
Reported as:
Number · percentage of participants
Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Threshold of <30 Millimetre Per Minute Per 1.73 Meter Square (mL/Min/1.73m^2)
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Threshold of <30 Millimetre Per Minute Per 1.73 Meter Square (mL/Min/1.73m^2)1.51.8
SecondaryPercentage of Participants With eGFR Threshold of <40 mL/Min/1.73m^2

The eGFR was calculated using the MDRD formula.

Time frame:
At 1 year post transplant
Reported as:
Number · percentage of participants
Percentage of Participants With eGFR Threshold of <40 mL/Min/1.73m^2
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With eGFR Threshold of <40 mL/Min/1.73m^29.55.7
SecondaryPercentage of Participants With eGFR Threshold of <50 mL/Min/1.73m^2

The eGFR was calculated using the MDRD formula.

Time frame:
At 1 year post transplant
Reported as:
Number · percentage of participants
Percentage of Participants With eGFR Threshold of <50 mL/Min/1.73m^2
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With eGFR Threshold of <50 mL/Min/1.73m^225.519.7
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Regression, Logistic · p = 0.1160 · Odds ratio (or): 1.431 · 95% CI 0.915 to 2.240
SecondaryPercentage of Participants With a Five-point Decline in eGFR

The eGFR was calculated using the MDRD formula.

Time frame:
From 30 days post transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants With a Five-point Decline in eGFR
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With a Five-point Decline in eGFR13.111.1
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Regression, Logistic · p = 0.4995 · Odds ratio (or): 1.212 · 95% CI 0.693 to 2.120
SecondaryeGFR at Day 30, Day 90, Day 180, Day 270 and Day 365

The eGFR was calculated using the MDRD formula.

Time frame:
Day 30, day 90, day 180, day 270 and day 365
Reported as:
Mean · mL/min/1.73 m^2
eGFR at Day 30, Day 90, Day 180, Day 270 and Day 365
mL/min/1.73 m^2Tacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Day 3050.86 ± 17.2752.72 ± 19.40
Day 9055.56 ± 16.0057.10 ± 19.99
Day 18056.81 ± 15.8458.33 ± 17.51
Day 27057.19 ± 16.8459.04 ± 18.19
Day 36558.25 ± 16.5160.94 ± 17.83
SecondaryPercentage of Participants With Graft Loss

Graft loss was defined as re-transplantation, transplant nephrectomy, or a return to dialysis for at least a six week duration, or participants' death.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants With Graft Loss
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Graft Loss1.51.4
SecondaryPercentage of Participants Who Died

Percentage of participants who died were reported.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants Who Died0.70.7
SecondaryPercentage of Participants With Biopsy-Proven Acute Rejection (BPAR)

Positivity was determined by local biopsy, central pathology, or reported adverse events.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)7.68.2
SecondaryPercentage of Participants Who Were Lost to Follow-up

Percentage of participants who were lost to follow-up were reported.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Lost to Follow-up
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants Who Were Lost to Follow-up00.7
SecondaryPercentage of Participants With Either Graft Loss, Death, BPAR or Lost to Follow-up

Percentage of participants with either graft loss, death, BPAR or lost to follow-up were reported.

Time frame:
From date of transplant until 1 year
Reported as:
Number · percentage of participants
Percentage of Participants With Either Graft Loss, Death, BPAR or Lost to Follow-up
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Either Graft Loss, Death, BPAR or Lost to Follow-up9.110.4
SecondaryPercentage of Participants With Any Antibody-Mediated Rejection (ABMR)

Percentage of participants with ABMR were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. A positive assessment is defined as antibody mediated changes that are diagnosed as either acute ABMR or chronic active ABMR.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Any Antibody-Mediated Rejection (ABMR)
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Any Antibody-Mediated Rejection (ABMR)1.60.7
SecondaryPercentage of Participants With Normal Biopsy Findings

Percentage of participants with normal biopsy findings were reported.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Normal Biopsy Findings
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Normal Biopsy Findings6.54.4
SecondaryPercentage of Participants With C4d Deposition Without Active Rejection

Percentage of participants with C4d deposition without active rejection were reported.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With C4d Deposition Without Active Rejection
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With C4d Deposition Without Active Rejection0.80.7
SecondaryPercentage of Participants With Acute ABMR

Percentage of participants with acute ABMR were reported.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Acute ABMR
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Acute ABMR1.60.7
SecondaryPercentage of Participants With Grade I, II and III Acute ABMR

Percentage of participants with grade I, II and III acute ABMR were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Acute ABMR was graded as Grade I: acute tubular necrosis-like -like minimal inflammation, Grade II: Capillary and or glomerular inflammation (ptc/g \>0) and/or thromboses, and Grade III: arterial - v3.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Grade I, II and III Acute ABMR
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Grade I500
Grade II50100
Grade III00
SecondaryPercentage of Participants With Chronic ABMR

Percentage of participants with chronic ABMR were reported.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Chronic ABMR
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Chronic ABMR00
SecondaryPercentage of Participants With Borderline Changes

Percentage of participants with borderline changes were reported.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Borderline Changes
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Borderline Changes14.614.7
SecondaryPercentage of Participants With Acute T-cell Mediated Rejection (TCMR)

Percentage of participants with acute TCMR were reported.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Acute T-cell Mediated Rejection (TCMR)
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Acute T-cell Mediated Rejection (TCMR)6.55.9
SecondaryPercentage of Participants With Chronic TCMR

Percentage of participants with chronic TCMR were reported.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Chronic TCMR
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Chronic TCMR2512.5
SecondaryPercentage of Participants With Grade I, II and III IFTA

Percentage of participants with Grade I, II and III IFTA were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. IFTA was graded as Grade I: mild interstitial fibrosis and tubular atrophy (\<25% of cortical area), Grade II: moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area), and Grade III: severe interstitial fibrosis and tubular atrophy/ loss (\>50% of cortical area).

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Grade I, II and III IFTA
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Grade I54.556.6
Grade II18.715.4
Grade III5.76.6
SecondaryPercentage of Participants With Any Additional Findings

Percentage of participants with any additional findings (other than Normal biopsy, borderline changes, acute and chronic ABMR, Grade I, II, and III ABMR, C4D deposition, acute and chronic TCMR, Grade I, II, and III TCMR, Grade I, II and III IFTA, acute tubular necrosis, interstitial nephritis, pyelonephritis, bk virus, calcineurin inhibitor toxicity, hemolytic uremic syndrome and recurrent disease) were reported.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Any Additional Findings
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Percentage of Participants With Any Additional Findings29.334.6
SecondaryPercentage of Participants With Glomerulitis (g) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No glomerulitis, Score 1= \<25% glomerulitis, Score 2= 25 to 75% glomerulitis and Score 3= \>75% glomerulitis.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Glomerulitis (g) Biopsy Score Assessed Using Banff Lesion Scores
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 089.490.4
Banff Lesion Score 15.76.6
Banff Lesion Score 24.11.5
Banff Lesion Score 300
Not able to score0.81.5
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.6327
SecondaryPercentage of Participants With Tubulitis (t) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No mononuclear cells in tubules or single focus of tubulitis only, Score 1= Foci with 1 to 4 mononuclear cells/tubular cross section (or 10 tubular cells), Score 2= Foci with 5 to 10 mononuclear cells/tubular cross section (or 10 tubular cells) and Score 3= Foci with \>10 mononuclear cells/tubular cross section or the presence of ≥2 areas of tubular basement membrane destruction accompanied by i2/i3 inflammation and t2 elsewhere.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Tubulitis (t) Biopsy Score Assessed Using Banff Lesion Scores
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 079.779.4
Banff Lesion Score 116.315.4
Banff Lesion Score 21.61.5
Banff Lesion Score 31.62.9
Not able to score0.80.7
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.9701
SecondaryPercentage of Participants With Intimal Arteritis (v) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No arteritis, Score 1= Mild to moderate intimal arteritis in at least 1 arterial cross section, Score 2= Severe intimal arteritis with at least 25% luminal area lost in at least 1 arterial cross section and Score 3= Transmural arteritis and/or arterial fibrinoid change and medial smooth muscle necrosis with lymphocytic infiltrate in vessel.

Time frame:
From date of transplant until month 14
Reported as:
Number · Percentage of Participants
Percentage of Participants With Intimal Arteritis (v) Biopsy Score Assessed Using Banff Lesion Scores
Percentage of ParticipantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 093.594.9
Banff Lesion Score 12.42.2
Banff Lesion Score 22.40
Banff Lesion Score 300
Not able to score1.62.9
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.3127
SecondaryPercentage of Participants With Mononuclear Cell Interstitial Inflammation (i) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No inflammation or in less than 10% of unscarred cortical parenchyma, Score 1= Inflammation in 10 to 25% of unscarred cortical parenchyma, Score 2= Inflammation in 26 to 50% of unscarred cortical parenchyma and Score 3= Inflammation in more than 50% of unscarred cortical parenchyma.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Mononuclear Cell Interstitial Inflammation (i) Biopsy Score Assessed Using Banff Lesion Scores
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 068.376.5
Banff Lesion Score 126.817.6
Banff Lesion Score 24.12.2
Banff Lesion Score 302.9
Not able to score0.80.7
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.0830
SecondaryPercentage of Participants With Glomerular Basement Membrane Double Contours (cg) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No GBM double contours by light microscopy (LM) or electron microscopy (EM), Score 1= No GBM double contours by LM but GBM double contours (incomplete or circumferential) in at least 3 glomerular capillaries by EM or Double contours of the GBM in 1-25% of capillary loops in the most affected nonsclerotic glomerulus by LM , Score 2= Double contours affecting 26 to 50% of peripheral capillary loops in the most affected-glomerulus and Score 3= Double contours affecting more than 50% of peripheral capillary loops in the most affected-glomerulus.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Glomerular Basement Membrane Double Contours (cg) Biopsy Score Assessed Using Banff Lesion Scores
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 093.593.4
Banff Lesion Score 15.73.7
Banff Lesion Score 201.5
Banff Lesion Score 300
Not able to score0.81.5
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.6022
SecondaryPercentage of Participants With Tubular Atrophy (ct) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No tubular atrophy, Score 1= Tubular atrophy involving up to 25% of the area of cortical tubules, Score 2= Tubular atrophy involving 26 to 50% of the area of cortical tubules and Score 3= Tubular atrophy involving in \>50% of the area of cortical tubules.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Tubular Atrophy (ct) Biopsy Score Assessed Using Banff Lesion Scores
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 020.321.3
Banff Lesion Score 153.755.9
Banff Lesion Score 219.515.4
Banff Lesion Score 35.76.6
Not able to score0.80.7
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.9249
SecondaryPercentage of Participants With Interstitial Fibrosis (ci) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= Interstitial fibrosis in up to 5% of cortical area, Score 1= Interstitial fibrosis in 6 to 25%of cortical area (mild interstitial fibrosis), Score 2= Interstitial fibrosis in 26 to 50% of cortical area (moderate interstitial fibrosis) and Score 3= Interstitial fibrosis in \>50% of cortical area (severe interstitial fibrosis).

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Interstitial Fibrosis (ci) Biopsy Score Assessed Using Banff Lesion Scores
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 021.120.6
Banff Lesion Score 152.856.6
Banff Lesion Score 219.515.4
Banff Lesion Score 35.76.6
Not able to score0.80.7
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.9136
SecondaryPercentage of Participants With Vascular Fibrous Intimal Thickening (cv) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No chronic vascular changes, Score 1= Vascular narrowing of up to 25% luminal area by fibrointimal thickening, Score 2= Vascular narrowing of 26 to 50% luminal area by fibrointimal thickening and Score 3= Vascular narrowing of more than 50% luminal area by fibrointimal thickening.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Vascular Fibrous Intimal Thickening (cv) Biopsy Score Assessed Using Banff Lesion Scores
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 033.336
Banff Lesion Score 140.741.2
Banff Lesion Score 22217.6
Banff Lesion Score 32.42.2
Not able to score1.62.9
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.8789
SecondaryPercentage of Participants With Arteriolar Hyalinosis (ah) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No periodic acid-Schiff (PAS)-positive hyaline arteriolar thickening, Score 1= Mild to moderate PAS-positive hyaline thickening in at least 1 arteriole, Score 2= Moderate to severe PAS-positive hyaline thickening in more than 1 arteriole and Score 3= Severe PAS-positive hyaline thickening in many arterioles.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Arteriolar Hyalinosis (ah) Biopsy Score Assessed Using Banff Lesion Scores
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 091.186.8
Banff Lesion Score 14.15.9
Banff Lesion Score 24.13.7
Banff Lesion Score 302.2
Not able to score0.81.5
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.5574
SecondaryPercentage of Participants With Peritubular Capillaritis (Ptc) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= Maximum number of leukocytes \<3, Score 1= At least 1 leukocyte cell in ≥10% of cortical PTCs with 3-4 leukocytes in most severely involved PTC, Score 2= At least 1 leukocyte in ≥10% of cortical PTC with 5-10 leukocytes in most severely involved PTC and Score 3= At least 1 leukocyte in ≥10% of cortical PTC with \>10 leukocytes in most severely involved PTC.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Peritubular Capillaritis (Ptc) Biopsy Score Assessed Using Banff Lesion Scores
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 091.190.4
Banff Lesion Score 13.35.1
Banff Lesion Score 24.92.9
Banff Lesion Score 300.7
Not able to score0.80.7
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.8150
SecondaryPercentage of Participants With Mesangial Matrix Expansion (mm) Biopsy Score Assessed Using Banff Lesion Scores

Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No more than mild mesangial matrix increase in any glomerulus, Score 1= At least moderate mesangial matrix increase in up to 25% of nonsclerotic glomeruli, Score 2= At least moderate mesangial matrix increase in 26% to 50% of nonsclerotic glomeruli and Score 3= At least moderate mesangial matrix increase in \>50% of nonsclerotic glomeruli.

Time frame:
From date of transplant until month 14
Reported as:
Number · percentage of participants
Percentage of Participants With Mesangial Matrix Expansion (mm) Biopsy Score Assessed Using Banff Lesion Scores
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Banff Lesion Score 087.891.2
Banff Lesion Score 18.96.6
Banff Lesion Score 22.40.7
Banff Lesion Score 300
Not able to score0.81.5
Statistical analysis
  • Tacrolimus, Extended Release (Astagraf XL®) Once Daily vs Tacrolimus, Immediate Release BID · Fisher Exact · p = 0.5673
SecondaryTime to First Occurrence of DSA

DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of DSA
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of DSANA ± NANA ± NA
SecondaryTime to First Occurrence of HLA-DQ DSA

Time to first occurrence of HLA-DQ DSA was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of HLA-DQ DSA
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of HLA-DQ DSANA ± NANA ± NA
SecondaryTime to First Occurrence of C1q-binding DSA

Time to first occurrence of C1q-binding DSA was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of C1q-binding DSA
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of C1q-binding DSANA ± NANA ± NA
SecondaryTime to First Occurrence of DSA IgG3 Isotype

Time to first occurrence of DSA IgG3 isotype was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of DSA IgG3 Isotype
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of DSA IgG3 IsotypeNA ± NANA ± NA
SecondaryTime to First Occurrence of IA

Time to first occurrence of IA was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of IA
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of IANA ± NANA ± NA
SecondaryTime to First Occurrence of TG on Biopsy

Time to first occurrence of TG on biopsy was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of TG on Biopsy
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of TG on BiopsyNA ± NANA ± NA
SecondaryTime to Occurrence of Death

Time to occurrence of death was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Median · days
Time to Occurrence of Death
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to Occurrence of DeathNA (NA to NA)NA (NA to NA)
SecondaryTime to First Occurrence of Local BPAR

Time to first occurrence of local BPAR was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of Local BPAR
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of Local BPARNA ± NANA ± NA
SecondaryTime to First Occurrence of Acute Forms of ABMR

Time to first occurrence of acute forms of ABMR was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of Acute Forms of ABMR
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of Acute Forms of ABMRNA ± NANA ± NA
SecondaryTime to First Occurrence of Chronic Forms of ABMR

Time to first occurrence of chronic forms of ABMR was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of Chronic Forms of ABMR
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of Chronic Forms of ABMRNA ± NANA ± NA
SecondaryTime to First Occurrence of Acute TCMR

Time to first occurrence of acute TCMR was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of Acute TCMR
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of Acute TCMRNA ± NANA ± NA
SecondaryTime to First Occurrence of Chronic TCMR

Time to first occurrence of chronic TCMR was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of Chronic TCMR
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of Chronic TCMRNA ± NANA ± NA
SecondaryTime to First Occurrence of Borderline Changes

Time to first occurrence of borderline changes was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of Borderline Changes
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of Borderline ChangesNA ± NANA ± NA
SecondaryTime to First Occurrence of IFTA

Time to first occurrence of IFTA was reported.

Time frame:
From date of transplant until 1 year
Reported as:
Mean · days
Time to First Occurrence of IFTA
daysTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Time to First Occurrence of IFTANA ± NANA ± NA
SecondaryPercentage of Participants With Treatment-emergent Adverse Event(TEAEs), Related TEAEs, Treatment-emergent Serious Adverse Event (TESAEs), Related TESAEs, TEAEs Leading to Discontinuation of Study Treatment and TEAEs Leading to Death

A TEAE was defined as an Adverse Event (AE) observed on or after the day of starting the administration of the test drug/comparative drug.

Time frame:
From first dose of study drug up to 7 days after last dose of study drug (up to 2 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Event(TEAEs), Related TEAEs, Treatment-emergent Serious Adverse Event (TESAEs), Related TESAEs, TEAEs Leading to Discontinuation of Study Treatment and TEAEs Leading to Death
percentage of participantsTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
TEAEs99.798.6
TEAEs related to study treatment77.870.7
TESAEs56.647.4
TESAEs related to study treatment27.423.7
TEAEs causing discontinuation of study treatment16.313.9
TEAEs leading to death0.70.7

Adverse events

Collected over From first dose of study drug up to 7 days after last dose of study drug (up to 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tacrolimus, Extended Release (Astagraf XL®) Once Daily2/288 (0.7%)163/288 (56.6%)285/288 (99%)
Tacrolimus, Immediate Release BID2/287 (0.7%)136/287 (47.4%)278/287 (96.9%)
Most frequent serious events
Showing 10 of 296
Most frequent serious events
EventTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
Acute kidney injuryRenal and urinary disorders26/28831/287
Urinary tract infectionInfections and infestations16/28811/287
HyperkalaemiaMetabolism and nutrition disorders15/2885/287
Kidney transplant rejectionImmune system disorders12/28814/287
DiarrhoeaGastrointestinal disorders7/28811/287
SepsisInfections and infestations7/28810/287
PneumoniaInfections and infestations10/2887/287
Blood creatinine increasedInvestigations10/2888/287
PyrexiaGeneral disorders9/2888/287
VomitingGastrointestinal disorders4/2887/287
Most frequent other events
Showing 10 of 67
Most frequent other events
EventTacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BID
DiarrhoeaGastrointestinal disorders128/288115/287
HypomagnesaemiaMetabolism and nutrition disorders124/288124/287
HypophosphataemiaMetabolism and nutrition disorders122/288122/287
NauseaGastrointestinal disorders101/288104/287
ConstipationGastrointestinal disorders90/288100/287
TremorNervous system disorders94/28884/287
Procedural painInjury, poisoning and procedural complications55/28891/287
HyperkalaemiaMetabolism and nutrition disorders81/28879/287
LeukopeniaBlood and lymphatic system disorders66/28858/287
VomitingGastrointestinal disorders41/28861/287

Baseline characteristics

The randomized set consisted of all participants who were randomized to receive the study drug (Astagraf XL or BID tacrolimus).

Age, Continuous
Age, Continuous(Years)Tacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BIDTotal
Mean49 ± 11.748.5 ± 11.648.8 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Tacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BIDTotal
Female11191202
Male189208397
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BIDTotal
Hispanic or Latino323466
Not Hispanic or Latino268265533
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tacrolimus, Extended Release (Astagraf XL®) Once DailyTacrolimus, Immediate Release BIDTotal
American Indian or Alaska Native415
Asian101424
Native Hawaiian or Other Pacific Islander213
Black or African American5867125
White212200412
More than one race000
Unknown or Not Reported141630
08

Study locations

30 sites
  • Site US10006
    Birmingham, Alabama 35294, United States
  • Site US10025
    Scottsdale, Arizona 85259, United States
  • Site US10031
    Los Angeles, California 90033, United States
  • Site US10005
    Sacramento, California 95817, United States
  • Site US10016
    San Francisco, California 94115, United States
  • Site US10024
    Aurora, Colorado 80045, United States
  • Site US10003
    New Haven, Connecticut 06510, United States
  • Site US10014
    Washington, District of Columbia 20007, United States
  • Site US10030
    Jacksonville, Florida 32224, United States
  • Site US10020
    Chicago, Illinois 60605, United States
  • Site US10010
    Chicago, Illinois 60611, United States
  • Site US10001
    Baltimore, Maryland 21201, United States
  • Site US10007
    Boston, Massachusetts 02114, United States
  • Site US10013
    Ann Arbor, Michigan 48109, United States
  • Site US10032
    Detroit, Michigan 48202, United States
  • Site US10029
    Minneapolis, Minnesota 55455, United States
  • Site US10027
    Rochester, Minnesota 55905, United States
  • Site US10019
    Livingston, New Jersey 07039, United States
  • Site US10004
    Buffalo, New York 14215, United States
  • Site US10037
    New York, New York 10032, United States
  • Site US10022
    New York, New York 10065, United States
  • Site US10028
    New York, New York 10467, United States
  • Site US10021
    Syracuse, New York 13210, United States
  • Site US10026
    Portland, Oregon 97210, United States
  • Site US10002
    Charleston, South Carolina 29425, United States
  • Site US10036
    Houston, Texas 77030, United States
  • Site US10018
    Salt Lake City, Utah 84112, United States
  • Site US10012
    Charlottesville, Virginia 22903, United States
  • Site US10008
    Falls Church, Virginia 22042, United States
  • Site US10023
    Madison, Wisconsin 53792, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Jun 2019, 33 months.

Results were first posted in Jun 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2016
First posted
Mar 30, 2016
StartActual
Sep 9, 2016
Primary completionActual
Jun 14, 2019
CompletionActual
Jun 14, 2019
Results first posted
Jun 29, 2020
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02723591
Responsible party
Sponsor
First posted
Mar 30, 2016
Start date
Sep 9, 2016
Primary completion
Jun 14, 2019
Completion
Jun 14, 2019
Results posted
Jun 29, 2020
Last update
Dec 18, 2024

Study contacts

Medical Monitor
study director · Astellas Medical Affairs, Americas

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion